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Eukaryotic aminopeptidase P1 (APP1), also known as X-prolyl aminopeptidase (XPNPEP1) in human
tissues, is a cytosolic exopeptidase that preferentially removes amino acids from the N-terminus of
peptides possessing a penultimate N-terminal proline residue. The enzyme has an important role in
the catabolism of proline containing peptides since peptide bonds adjacent to the imino acid proline
are resistant to cleavage by most peptidases. We show that recombinant and catalytically active
Caenorhabditis elegans APP-1 is a dimer that uses dinuclear zinc at the active site and, for the ﬁrst
time, we provide structural information for a eukaryotic APP-1 in complex with the inhibitor,
apstatin. Our analysis reveals that C. elegans APP-1 shares similar mode of substrate binding and
a common catalytic mechanism with other known X-prolyl aminopeptidases.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metallopeptidases make up around a third of all known proteo-
lytic enzymes and use an activated water molecule coordinated to
a divalent metal ion as the catalytic nucleophile for peptide bond
hydrolysis [1,2]. The active sites of most metalloproteases contain
a single metal ion; however enzymes belonging to the M24 family
possess two metal ions that co-catalytically activate a bridging
water molecule [2]. M24 metallopeptidases are also characterised
by having a common protein fold in their catalytic domain called
the ‘’pitta-bread’ fold that was ﬁrst described in Pseudomonas
putida creatinase [3]. The family is split into two subfamilies;
subfamily M24A contains the methionine aminopeptidases(MetAP), whilst subfamily M24B includes two proline-speciﬁc pep-
tidases, X-pro dipeptidase (prolidase) and X-prolyl aminopeptidase
(aminopeptidase P, APP) [2]. Proline is different from the other
common proteinogenic amino acids in that it is an imino acid
where the side chain is part of a ﬁve-membered ring that includes
both the Ca and the amino nitrogen atom. The resulting ring struc-
ture restricts free rotation around the Ca–N bond and the presence
of a secondary amine means that the nitrogen cannot participate in
hydrogen bonds with carbonyls [4]. As a consequence of the con-
formational rigidity conferred by the cyclic side-chain, peptide
bonds involving proline are often resistant to hydrolysis by
peptidases [5,6]. The protection conferred by the positioning of
proline in a peptide sequence has often been exploited in
nature to stabilize biologically active peptides from unwanted
degradation and inactivation. However, there is a need for pro-
line-speciﬁc peptidases that can be used strategically to terminate
the activity of peptide hormones (e.g. bradykinin) and for the cat-
abolism of peptides derived from proline-rich proteins, such as col-
lagen [7–9].
Of the proline-speciﬁc peptidases only APP and prolidase are
capable of cleaving substrates at the N-terminus where proline is
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Xaa-Pro peptide bond from oligopeptides and is distinct from pro-
lidase, which acts only on dipeptides. APP activity, whilst not
essential in Escherichia coli [11], is wide spread among bacterial
genomes, including the minimal genome of Haemophilus inﬂuenza.
In eukaryotes, there are three APP homologues, a soluble cytosolic
form known as APP-1, a membrane bound form called APP-2 and a
mitochondrial APP-3 [12–15]. APP-3 is evolutionarily distinct from
the other APP enzymes, sharing just 12% and 16% sequence identity
with APP-1 and APP-2, respectively. Within animals, APP-1 is dis-
tributed widely among various tissues and cell types. In mammals,
APP-1 has been found in every tissue examined with strongest
expression levels in the intestine, testis, kidney and brain.
Similarly, Western blot analysis using a speciﬁc antibody showed
APP-1 expression in the gut, brain, testes and ovaries of adult
Drosophila melanogaster [16] with RNA levels highest in the adult
midgut and renal tubules [17]. In the free-living nematode,
Caenorhabditis elegans, the expression of an APP-1-GFP fusion pro-
tein was limited to the intestine, indicating a more restricted tissue
distribution [18].
One of the proposed roles for APP-1 is in the breakdown of
imino-peptides generated during protein catabolism. A deﬁciency
in APP-1 activity in human and mouse results in a large increase
in proline-containing oligopeptides in the urine (peptiduria) and
severe developmental retardation, possibly from the failure to
clear peptides from nerve cells [19,20]. In the malaria parasite,
Plasmodium falciparum, APP-1 is localised to the food vacuole of
the intraerythrocytic stage where haemoglobin is digested [21].
The ectoenzyme APP-2 has a more speciﬁc role in the metabolic
inactivation of signalling peptides (e.g. bradykinin and substance
P) at cell surfaces [22–23]. APP-3 is involved in proteolytic process-
ing and stabilization of mitochondrial proteins in yeast, but the
substrates and metabolic role of the mammalian enzyme have
not yet been precisely deﬁned [24]. However, APP-3 is physiologi-
cally important since mutations in XPNPEP3, the human APP-3
gene, result in autosomal recessive kidney disease nephronophthi-
sis [15].
E. coli APP-1 and human cytosolic APP-1, to date, are the only
two enzymes to have had their three-dimensional structures
determined by X-ray crystallography [25–29]. Here, we report
the crystal structures of native as well as apstatin-bound C. elegans
APP-1. Apstatin is a selective inhibitor of aminopeptidase P,
designed speciﬁcally to test its effect on bradykinin degradation
in rat lung [30]. To our knowledge this is the ﬁrst structure of an
inhibitor-bound eukaryotic aminopeptidase P. Although a simple
metazoan, C. elegans shares many essential molecular pathways
with higher animals and has been exploited extensively as a
powerful model to study molecular mechanisms linked to human
diseases [31–32]. In addition the nematode has been the subject
of genome scale effort to determine three-dimensional protein
structures and new protein folds by X-ray crystallography and
NMR [33]. A better understanding of the structure/function of
APP-1 in C. elegans will help shed light on evolutionarily conserved
functions of APP-1 in other animals, including humans. This spe-
cialist aminopeptidase is also of interest in the development of
safer methods for the treatment of diseases caused or transmitted
by parasitic nematodes and arthropods; for example, APP-1 has
recently been proposed as a target for the development of anti-
malarial protease inhibitors.
Unlike the bacterial enzyme, eukaryotic APPs are larger (typi-
cally 620–650 residues long compared to 450), and whilst they
share some clear primary sequence homology in the C-terminal
catalytic domain, there is very little, if any, sequence homology
in the N-terminal regions of these proteins. As such E. coli pos-
sesses relatively low sequence identity with human APP-1 and
APP-2 (11% and 12% respectively), whilst C. elegans APP-1possesses 40% and 30% identity (58% and 48% similarity) with the
two human homologues respectively. The structure of C. elegans
APP-1 bound to the inhibitor, apstatin, provides a better basis for
the future development of novel approaches for parasite control.
It would also help to provide a more accurate modelling of
human APP-2, a potential drug target for prevention of myocardial
infarction [34].
2. Results
2.1. Analytical ultracentrifugation
A sedimentation velocity experiment was carried out to estab-
lish the oligomerisation state of the recombinant C. elegans APP-
1. Three species are evident from a plot of the molar mass (Da)
against their relative concentrations (M) (Fig. 1A). Molecular
masses of these species were 64,066 Da, 143,268 Da and
250,789 Da, corresponding to 2.1%, 77.5% and 9.6% of the total pro-
tein respectively. Whilst the major species is clearly a dimer,
detectable amounts of monomer and tetramer are also present.
2.2. Mass spectrometry
APP-1 (0.3 ml at 1.3 mg/ml) was desalted by dialysis against
Millipore water for electrospray mass spectrometry. Under acidic
conditions a major peak was observed at 71977.2 Da (Fig. 1B),
which corresponds well with the mass of the His-tagged APP-1
after removal of the start methionine (calculated mass
71975.5 Da). The protein was also analysed under neutral condi-
tions (pH 7.0) to see whether any oligomerisation could be
observed. The spectrum showed a peak at 144718.6 Da indicative
of a dimer (Fig. 1C).
2.3. Inductively coupled plasma mass spectrometry
Puriﬁed recombinant APP-1 was dialyzed against chelex treated
water to remove contaminating metal ions. A sample of protein
and a control sample of buffer were subjected to metal ion analysis
by ICP-MS. The protein was quantiﬁed at 1.43 mg/ml, or 19.5 lM
compared to a Zn2+ concentration of 21.6 lM, indicating a protein
to zinc ratio of 1:1.1, with only negligible amounts of manganese
and cobalt.
2.4. Activity of recombinant APP-1
Puriﬁed APP-1 converted bradykinin to des-Arg-bradykinin at a
rate of 107 pmol/h/ng of protein and this activity was inhibited by
10 lM apstatin (92% inhibition). The enzymatic properties of the
enzyme have been described previously [18].
2.5. Quality of the structure of C. elegans APP-1
The structure of C. elegans APP-1 was determined at 1.93Å res-
olution (Fig. 2A and Table 1). The crystals contained two molecules
in the asymmetric unit, each comprising the full complement of
the APP-1 amino acid sequence. Analysis of the Ramachandran plot
[35] indicated that 97% of residues fall in the most favoured region
with no residues in the disallowed region of the plot. Although
both the polypeptide chains are complete with the exception of
N-terminal His6 tag, residues 69, 93, 101, 133, 158, 159, 234,
280, 394, 396, 398, 437, 528 and 598 from chain P (MolA) and resi-
dues 69, 133, 159, 234, 280, 394, 396, 398, 437 and 616 from chain
Q (MolB) have patchy electron density for their side chains.
Residues 505–508 that form part of a solvent exposed loop region
have not been modelled in the structure as electron density for this
region could not be observed. None of these residues form the
Fig. 1. (A) Sedimentation velocity analytical ultracentrifugation experiment. APP-1 centrifuged at 40 K rpm and protein sedimentation observed by A275 (purple) and Rayleigh
interference (pink). Plot of molecular mass (Da) against the concentration per Dalton c(M) such that after integration area under each peak is equal to the loading
concentration of that species. The three main species are 64,066 Da (2.1% of total), 143,268 Da (77.5%) and 250,789 Da (9.6%). (B) Electrospray mass spectrometry of APP-1
under acidic conditions. Spectrum shows a single peak at 71977.2 Da, which ﬁts well with the predicted mass of His-tagged APP-1 monomer. (C) Electrospray mass
spectrometry of APP-1 under neutral conditions. Spectrum shows a peak at 144718.6 Da, which agrees with the expected mass of a dimer.
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Fig. 2. (A) Ribbon representation of C. elegans APP-1. The secondary structure elements are coloured green-cyan (b-strands) and purple (a-helices). The Zn2+ ions are
represented as spheres in grey. The N- and C-terminal ends of both monomers have been labelled. (B) Stereoview of the active site in native C. elegans APP-1 structure. The
interacting residues are coloured according to their elements: carbon, cyan; nitrogen, blue; oxygen, red. The Zn2+ ions are shown in grey. Active site water molecule is shown
in dark blue.
S. Iyer et al. / FEBS Open Bio 5 (2015) 292–302 295dimer interface and thus do not affect our analysis of the interface.
Average temperature factors of 32.1 Å2 for MolA and 31.8 Å2 for
MolB were calculated. A total of 597 water molecules and four
Zn2+ ions were also identiﬁed in the asymmetric unit, with an aver-
age B-factor of 34.6 Å2 and 27.8 Å2, respectively. The atomic coor-
dinates and structure factors for both the unliganded APP-1 and
apstatin-bound APP-1 have been deposited in the Protein Data
Bank with accession codes 4S2R (http://www.rcsb.org/pdb/
search/structidSearch.do?structureId=4S2R) and 4S2T (http://
www.rcsb.org/pdb/search/structidSearch.do?structureId=4S2T).
2.6. Overall structure of C. elegans APP-1
The ﬁnal reﬁned structure of C. elegans APP-1 (Fig. 2A) is topo-
logically similar to the structure of human X-prolyl aminopepti-
dase. The C. elegans APP-1 structure can be divided into three
domains: an N-terminal domain comprising residues 1–163, a
middle domain consisting of residues 164–318 and the C-terminal
domain consisting of residues 319–616. The program DSSP [36]was used to assign secondary structure elements in each domain.
The N-terminal domain and the middle domain are structurally
similar to one another. The core of these domains is composed of
a six-stranded b-sheet ﬂanked by the same number of a-helices.
All the b-strands in each of the two domains point in the same
direction except strand 2 of each domain, which points in the
opposite direction. The C-terminal domain also consists of 6 a-he-
lices. These helices ﬂank the 9 b-strands of this domain, 5 of which
form an anti-parallel b-sheet.
2.7. Dimer interface
The dimeric state of recombinant C. elegans APP-1 was con-
ﬁrmed by solution studies, including AUC and mass spectrometry
(Fig. 1B and C). This is consistent with the homodimer observed
in the asymmetric unit. The two protomers (MolA and MolB) are
held together mainly via hydrophobic interactions. Interfacing
residues run along the entire length of the dimer with each subunit
contributing 54 residues to the dimer interface. Around 7.5%
Table 1
Crystallographic data and reﬁnement analysis.
Native C. elegans APP-1 C. elegans
APP-1apstatin complex
Space group C2 C2
Unit cell a = 141.4 Å, b = 87.9 Å,
c = 114.7 Å
a = 140.6 Å, b = 86.8 Å,
c = 113.1 Å
b = 115.9 b = 115.9
Resolution range
(Å)
30–1.93 (1.98–1.93) 30–2.15 (2.21–2.15)
Redundancy 3.7 (2.9) 2.6 (1.8)
I/rI 14.9 (1.9) 13.3 (2.4)
Completeness
(%)
97.2 (82.7) 91.8 (60.4)
Rp.i.m (all I+ and
I)
0.044 (0.408) 0.045 (0.328)
No. of reﬂections
Total 339,579 (16,893) 156,269 (5,362)
Unique 91,904 (5,753) 61,133 (2,969)
Wilson B (Å2) 26.3 44.3
Rwork (%) 16.3 20.4
Rfree (%) 21.4 24.7
Average B values (Å2)
Protein 31.9 35.6
Solvent 34.6 32.5
Ligand – 40.1
Ions 27.8 (Zn2+ ions) 49.9 (Zn2+ ions)
24.3 (SO42 ions)
Root mean square deviation
Bond lengths (Å) 0.007 0.008
Bond angles () 1.03 1.217
Values in the parentheses refer to the highest resolution shell.
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buried upon dimer formation, calculated using the PISA
interface server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.
html). There are 9 potential hydrogen bonds that help stabilize
the interaction between the two subunits, of which one interaction
is a salt bridge between Nf of Lys136 and Oe2 of Glu301. The bur-
ied interface at the APP-1 dimer is of considerable size and con-
tains approximately one polar interaction per 220 Å2.
2.8. Active site
The catalytic site of APP-1 (Fig. 2B) is located in a dipped surface
on the ﬁve-stranded anti-parallel b-sheet of the C-terminal domain.
The active site consists of residues Asp413, Asp424, His487, His496,
Glu522 and Glu536, all of which coordinate with the dinuclear Zn2+
centre. The two catalytic Zn2+ ions differ in their geometry, in that
one Zn2+ ion displays octahedral coordination geometry by inter-
acting with all the residues listed above. The second Zn2+ ion on
the other hand shows a distorted square-pyramidal geometry
where a water molecule and four carboxylate atoms from Asp413,
Asp424, Glu522 and Glu536 form the donor atoms.
2.9. Structure of the C. elegans APP-1apstatin complex
The complex of C. elegans APP-1 with apstatin was determined
at 2.15 Å resolution (Fig. 3A). The structure consists of two mole-
cules in the asymmetric unit, with four Zn2+ ions (two per mono-
mer) and one molecule of apstatin per molecule of APP-1. Both
the polypeptide chains are complete with the exception of N-term-
inal His6 tag. However, residues 69, 93, 101, 133, 158, 159, 274,
280, 394, 396, 398, 437, 528 and 607 from chain P (MolA) and resi-
dues 24, 69, 101, 133, 159, 192, 280, 394, 396, 398, 437, 528 and
604 from chain Q (MolB) show very patchy electron density for
their side chains. Similar to the native APP-1 structure, the residues
of the solvent exposed loop, 505–508, have not been modelled in
the structure due to lack of electron density. A total of 355 watermolecules along with seven SO42-ions were modelled in the
structure.
Weak electron density was identiﬁed for apstatin in both the
subunits in the asymmetric unit of crystalline C. elegans APP-1
(Fig. 3B). Apstatin was modelled at the active site based on the
E. coli structure using this electron density as a guide. The binding
of apstatin does not cause any major structural change. The back-
bone of the apstatin-bound C. elegans APP-1 superposes on the Ca
atoms of the native structure with an r.m.s.d of 0.3 Å. The inhibitor,
sitting at the bottom of the active-site cleft, makes 13 potential
hydrogen-bonding interactions with the enzyme and one bond
with a water molecule (Table 2). The amino acid residues that con-
tribute to the bonding interactions between the inhibitor and the
enzyme are Arg78, Phe378, His392, Asp413, Asp424, His487,
His496, Glu522 and Glu536. Apstatin displaces a water molecule
present in native C. elegans APP-1 to coordinate with the metal ions
in the dinuclear active site. The inhibitor also makes a number of
putative van der Waals interactions with the residues of C. elegans
APP-1 (Table 2). The phenyl ring of the ﬁrst residue of apstatin
(pseudo-Phe), by itself, makes several such van der Waals contacts.
The ring ﬁts between His392 and Phe378, making loose stacking-
interactions with the two rings on either side of it. The second resi-
due of the apstatin makes contact with Arg78, His392, His483,
Glu522 and Arg534. The prolidyl ring of the third apstatin residue
interacts with all the active site residues as well as Phe378 and
His392 (Fig. 3B). The two C-terminal residues of the inhibitor point
towards the solvent exposed loop comprising residues 505–509.
However, since these residues have not been modelled in the struc-
ture, no potential hydrogen bonding interactions or van der Waals
contacts could be observed.3. Discussion
3.1. Metal ion dependence of C. elegans APP-1
The metal ion content of puriﬁed recombinant His-tagged APP-
1 was analysed by ICP-MS, which revealed a 1:1.1 M ratio of pro-
tein to Zn2+ with only negligible quantities of Mn2+ and Co2+. The
near 1:1 ratio is consistent with inductively coupled plasma atomic
emission spectroscopy (ICP-AES) results for a number of puriﬁed
clan MG enzymes which showed the presence of 1 M equivalent
metal ion. These included 1 M equivalent Co2+ in E. coli MAP [37],
one Zn2+ in Pyrococcus furiosus MAP [38], one Co2+ in recombinant
P. furiosus prolidase [39], one Zn2+ in puriﬁed porcine APP-2 [40]
and one Mn2+ ion in recombinant human APP-1 [41]. However,
the metal content and metal-protein stoichiometry can be inﬂu-
enced by the cell culture conditions employed to express the
recombinant protein and especially whether the medium has been
enriched with a particular metal. For example, the human APP-1
used for structural studies was expressed in E. coli cultured in
Mn2+-enriched LB medium under slow growth conditions con-
tained 1.79 Mn2+ ions per protein monomer, but when expressed
in plain LB medium the metal ion content changed to a mixture
of Mg2+, Mn2+ and Fe2+ in a ratio of 0.41, 0.70 and 0.73 [29].
Nevertheless the molar ratio of total divalent metal to APP-1
monomer remained close to 2:1. This ratio is consistent with the
results from several crystallographic studies of clan MG peptidases,
including data presented here for C. elegans APP-1 that reveal two
metal ion binding sites in the active site, and most proposed
mechanisms for these enzymes predict the nucleophile to be a
bridging water (or hydroxide) ligand between these two metals.
Whilst some clan MG peptidases, such as E. coli APP [25] have been
crystallized with a single non-catalytic metal ion in the active site,
it was only recently that the crystal structure of a ‘‘mono-
metalated’’ MAP structure was published containing a single
Fig. 3. (A) Ribbon representation of C. elegans APP-1 in complex with apstatin. The secondary structure elements are coloured green (b-strands) and orange (a-helices). The
Zn2+ ions are represented as spheres in grey. The N- and C-terminal ends of both monomers have been labelled. Apstatin is shown at the active site as a ball-and-stick model
in raspberry red. (B) Stereoview of the active site in the complex of C. elegans APP-1 with apstatin. The interacting residues are coloured orange. The inhibitor, apstatin,
coloured as above is shown in ball-and-stick. Fo-Fc omit map for the bound inhibitor is shown in grey. The Zn2+ ions are shown in cyan with the electron density shown in
magenta, contoured at 3r.
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tightly regulating the concentration of various metal ions within
the crystallization solution. As mentioned above, ICP-AES and
ICP-MS identiﬁed Mn2+ as the divalent cofactor in human APP-1.
However ICP-MS and crystallographic analysis of C. elegans cytoso-
lic APP-1 has shown the presence of Zn2+, with only negligible
quantities of Mn2+ and Co2+. Interestingly, mammalian mem-
brane-bound APP-2 is also a zinc metalloenzyme [13].
3.2. C. elegans APP-1 forms a dimer
Recombinant His-tagged C. elegans APP-1 forms a dimer.
Electrospray mass spectrometry under neutral conditions showed
two peaks, one corresponding to the 72 kDa monomer and thesecond with a mass 144 kDa, presumably corresponding to a
dimer. To conﬁrm that APP-1 forms a dimer in solution a sedi-
mentation velocity analytical ultracentrifugation experiment was
performed which showed that 80% of the total protein was present
as a species with a mass of 143 kDa (Fig. 1A). The protein also crys-
tallizes as a dimer in the asymmetric unit, in both native and inhi-
bitor bound states (Figs. 2A and 3A).
Unlike the recombinant His-tagged C. elegans APP-1, the E. coli
homologue forms a tetramer where two monomers form a dimer
through interactions between the C-terminal domains, and then
these two dimers interact through their N-terminal domains
[26]. Therefore the possibility that the N-terminal His-tag and
linker are disrupting formation of a tetramer in the His-tagged
C. elegans APP-1 cannot be excluded. However, analysis of the
Table 2
Potential molecular interactions between APP-1 residues and apstatin. Interactions
were identiﬁed using CONTACT in CCP4 [52].
APP-1 residues van der Waals contacts Hydrogen bonds
Apstatin APP-1 Distance (Å)
Tyr43 11 OBE WATER 2.8
Arg78 10 OAXO NH1 3.0
NH1 2.5
Phe378 10 – – –
Ile381 3 – – –
His392 15 O NE2 3.1
Asp413 6 OAD OD2 3.3
NAC OD1 3.2
NAC OD2 2.9
Asp424 – – –
His483 6 – – –
Gly484 4 – – –
Gly486 1 – – –
His487 2 OAM NE2 3.0
His496 6 OAM NE2 2.5
Glu522 10 OAD OE1 2.7
N OE1 3.06
OAM OE2 3.2
Arg534 4 – – –
Glu536 2 OAD OE1 3.3
OAD OE2 3.2
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by various size exclusion techniques suggest that it is a commonFig. 4. Stereo superposition of the Ca traces of C. elegans APP-1 and human APP-1. (A) Hu
N- and C-termini are labelled. (B) Stereo superposition of the residues at the active site. Costructural feature of these enzymes to form dimers in solution at
physiologically relevant salt concentrations [41,43,44]. Rat brain
APP-1, known to form a dimer in the presence of 140 mM salt,
forms trimers in the absence of NaCl [22]. Whilst cytosolic APP-1
forms dimers, the membrane bound APP-2 appears to differ with
a range of oligomerisation states depending on the species the
enzyme is from. For example, bovine lung APP-2 forms a tetramer
[45], rat lung APP-2, varies between a trimer and a tetramer
depending on NaCl concentration [46] and pig kidney APP-2 forms
a trimer [40]. The physiological relevance of this difference
between APP-1 and APP-2 is unclear.
3.3. Comparison with human X-prolyl aminopeptidase
Human APP-1 structure, when elucidated, revealed for the ﬁrst
time a novel three-domain structure for an X-prolyl peptidase [29].
Comparing this modular arrangement with that of C. elegans APP-1
it becomes obvious that the three domains in our structure occupy
similar statutory positions (Fig. 4A). C. elegans APP-1 is, however,
the ﬁrst structure of a eukaryotic APP-1 with an inhibitor molecule
bound at the active site. The human APP-1 structure solved pre-
viously is a native structure. Like C. elegans APP-1, human APP-1
is around 620 amino acids long, but despite topological similarities,
a lot of conformational differences can be observed when the two
structures are compared. The most signiﬁcant of the differences
can be seen in the N-terminal region of the structures (Fig. 4A).
Superposition of the human enzyme on to that of C. elegans leadsman APP-1 is shown in raspberry red and the C. elegans APP-1 is shown in palecyan.
lours correspond as above. Residues from the C. elegans APP-1 structure are labelled.
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correspondence between the two increases, with an r.m.s.d. of
1.1 Å over 433 Ca atoms, when the structures are superposed after
the removal of the N-terminal domain. There are also some signiﬁ-
cant differences seen in the positioning of the catalytically impor-
tant residues, especially the residue corresponding to His392,
which seems further away from the active site in human APP-1
(Fig. 4B). Also, residue Arg77 in human APP-1 (Arg78 in C. elegans
APP-1) is further away from the active site. One must, however,
bear in mind that the human APP-1 structure does not have apsta-
tin bound at the active site. The orientations and positioning of
these side chains in the structure of the human enzyme might be
different when bound to apstatin.
3.4. Comparison between C. elegans APP-1apstatin structure and
E. coli APP-1apstatin structure
Structure superposition of C. elegans APP-1 and E. coli APP-1 [27]
shows that even though r.m.s. difference between the positions of
corresponding atoms is 2.6 Å, the two share a conserved catalytic
domain and active site (Fig. 5A). Superposition of the active sites
from the two complexes (Fig. 5B) reveals a close correspondence
between the coordination geometries and the conformation of
the residues surrounding the two metal ions at the dinuclear active
site. E. coli APP-1 requires Mn2+ for its activity, whereas C. elegans
APP-1 has Zn2+ as the active site metal. We used LIGPLOT [47] to
generate schematic 2D representation of the putative molecular
interactions between APP-1 and the ligand in the two apstatin
complexes to simplify visualisation of the active site.Fig. 5. Comparison of C. elegans APP-1apstatin and E. coliAPP-1. (A) Stereo superposition
in splitpea green and the C. elegans APP-1apstatin is shown in orange. N- and C-termini
interactions between APP-1 and the ligand in the two apstatin complexes. (C) Schemati
both complexes.The catalytic mechanism of E. coli APP-1 has been extensively
studied [25,48]. Given the close agreement between the active sites,
it is likely they share the same enzymatic mechanism. In the E. coli
structure, the catalytic His243 is thought to participate in hydrogen
bonding interactionwith the proline residue of the substrate to sta-
bilise its binding at the active site (Fig. 5C). Mutation of this residue
to alanine leads to a signiﬁcant decrease in the catalytic efﬁciency
of the E. coli enzyme. Based on the fact that this histidine is con-
served across all X-prolyl aminopeptidases, there is little doubt that
His392 plays a similar important role in C. elegans APP-1. In the pre-
sent complex structure, this residue makes 15 potential van der
Waals contacts at the active site along with one potential hydro-
gen-bonding interaction (Fig. 5C). Also seen in the present structure
is the side chain of Arg78 pointing towards the active site, forming
two hydrogen bonds with the inhibitor molecule (Fig. 5C). Arg78
probably helps to hold the inhibitor in place in the active site by
means of this hydrogen bond. The equivalent residue is however
missing in E. coli APP-1 due to the lack of the N-terminal domain
(domain I). Even though the general positioning of the inhibitor
molecule at the active site is similar in both our complex and the
E. coli APPapstatin complex (Fig. 5B), the position of the second,
speciﬁcity-conferring prolidyl ring in our complex is such that it
makes contacts with the enzyme at Arg78 as well as His487 in addi-
tion to its interactions with ﬁve other APP-1 residues (Phe378,
His392, His496, Arg534) and the metal-coordinating residue,
Glu522 via the active site Zn2+ ions. Counterpart residues in the
E. coli APPapstatin complex are Tyr229, His350, His361, Arg404
and Glu383, respectively [27]. The two complexes also show the
C-terminal residues protruding in two opposite direction from theirof the Ca traces of C. elegans APP-1apstatin and E. coliAPP-1. E. coliAPP-1 is shown
are labelled. (B) Superposition of the schematic 2D representation of the molecular
c 2D representation of the molecular interactions between APP-1 and the ligand in
300 S. Iyer et al. / FEBS Open Bio 5 (2015) 292–302respective active sites (Fig. 5B). But since both complexes did not
show sufﬁciently resolved density of the last two apstatin residues,
it is entirely possible that the orientation and positioning might be
the same in the two complexes. .
4. Conclusions
The striking similarity between the structures of X-prolyl ami-
nopeptidases reveals similar polypeptide topologies and almost
identical active sites, suggesting that these enzymes also share
similar modes of substrate binding and a common catalytic mecha-
nism. In this paper we have presented the structure of C. elegans
APP-1 both in its native form as well as in complex with the inhi-
bitor, apstatin. Comparison of all published X-prolyl aminopepti-
dase structures reveals that the residues that have been shown
to interact with apstatin in one enzyme are either strictly or con-
servatively conserved in the others. It can be assumed that the
interactions observed in the complexes of apstatin with E. coli
APP-1 and C. elegans APP-1 would be replicated to some extent
in the complex of human APP-1 with apstatin. Although it is still
not possible to explain the absolute requirement of a penultimate
N-terminal proline residue in substrates, the structure of the mod-
elled apstatin-C. elegans APP-1 complex provides valuable insights
into the speciﬁcity of the enzyme. The structure provides a scaffold
for the design of inhibitors that are speciﬁc for C. elegans APP-1 by
taking advantage of the structural differences and similarities
between the different enzyme-inhibitor complexes.5. Materials and methods
5.1. Cloning, expression, and puriﬁcation of recombinant C. elegans
APP-1
C. elegans APP-1 cDNA was PCR-ampliﬁed using Expand High
Fidelity Enzyme (Roche) and the following primers: forward pri-
mer 50-CATATGACAGCATTGGAAAAACTC-30 and reverse primer 50-
CATATGTTAGATTGGTTTACAGGC-30. The PCR product was cloned
into pET19b plasmid (Novagen), and the resulting expression plas-
mid was transformed into E. coli BL21 star (DE3) strain
(Stratagene).
Cells harbouring the pET19b-APP-1 expression plasmid were
grown in autoinduction media [49] at 25 C and harvested 40 h
post inoculation. Cells obtained from 0.5 L of bacterial culture were
resuspended in 20 ml of lysis buffer containing 10 mM Tris/HCl,
0.3 M NaCl at pH 8 supplemented with 20 mM imidazole. Cells
were lysed using a cell disruptor at 20,000 PSI. The lysate was cen-
trifuged for 30 min at 70,000g at 4 C to remove cellular debris.
The supernatant was loaded onto a 5-ml HiTrap FF column (GE
Healthcare). The column was washed with lysis buffer to remove
unbound material, following which the bound protein was eluted
using 0.3 M imidazole in lysis buffer. The eluate from the HiTrap
FF column was concentrated and further puriﬁed on Superdex
200 (GE Healthcare), equilibrated with 10 mM Tris/HCl, pH 8.0,
and 150 mM NaCl. Purity and homogeneity of the protein were
monitored by SDS–PAGE at every step. APP-1 was concentrated
to 3 mg/ml for the purpose of crystallization. The puriﬁed protein
was authenticated by mass spectrometry and western blot
analysis.
5.2. Protein crystallization, data collection, and processing
Crystals were grown using the sitting drop vapour diffusion
method at 16 C. Crystallization buffer containing 17.5% PEG
3350, 0.1 M Bis-tris propane, pH 8.5, and 0.2 M sodium malonate
was mixed with an equal volume of protein solution. A completedataset to 1.9 Å resolution was collected from a single crystal using
the Diamond Light Source, UK. Crystals for the complex of C. ele-
gans APP-1 with apstatin were obtained by overnight incubation
of the protein at 3 mg/ml with 10 mM inhibitor at 4 C prior to set-
ting up crystallizations. Crystals of the complex grew at the pH 7.5
in 20% PEG3350. A complete dataset to 2.15 Å resolution was col-
lected from a single crystal using the Diamond Light Source, UK.
Data were processed and scaled using HKL2000 [50] in the mono-
clinic space group C2.
5.3. Structure determination and reﬁnement
The structure of C. elegans APP-1 was determined by maximum
likelihood molecular replacement using the program PHASER from
CCP4 suite [51,52]. The initial search model used was human
cytosolic APP-1 (PDB: 3CTZ). The asymmetric unit consists of an
APP-1 dimer. Iterative rounds of model building with the program
COOT [53] and reﬁnement with the program PHENIX [54] resulted
in the ﬁnal native APP-1 structure for all data between 40 and 1.9 Å
resolution. The structure of C. elegans APP-1 in complex with apsta-
tin was determined using the native structure solved above. The
asymmetric unit consists of two molecules of APP-1. Iterative
rounds of model building with the program COOT [53] and reﬁne-
ment with the programs PHENIX [54] in the early stages and
REFMAC from CCP4 suite [52,55] in the later stages resulted in
the ﬁnal APP-1apstatin complex structure for all data between
40 and 2.15 Å resolution. Structure validation was carried out
using MOLPROBITY [56,57] and the RCSB PDB Validation Suite
(http://deposit.rcsb.org/validate/). Reﬁnement statistics for the
ﬁnalised structures are provided in Table 1. Figures were prepared
using PYMOL (http://www.pymol.org). The atomic coordinates and
structure factors for native C. elegans APP-1 (PDB: 4S2R) and its
complex with apstatin (PDB: 4S2T) have been deposited with the
Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, New Brunswick, NJ, USA
(http://www.rcsb.org/).
5.4. Analytical ultracentrifugation
1 ml of 0.3 mg/ml APP-1 was dialyzed against 50 ml 10 mM
Tris/HCl pH 7.5, 150 mM KCl overnight. Both protein and a refer-
ence sample of the dialysis buffer were submitted to to the
Astbury Centre for Biomolecular Interactions, University of Leeds,
for ultracentrifugation. Samples (0.4 ml) were centrifuged in
1.2 cm path-length 2-sector aluminium centre-piece cells (sample
in RH sector, reference buffer in LH sector) with sapphire windows
in a 4-place An-60 Ti analytical rotor running in an Optima XL-I
analytical ultracentrifuge (Beckman Instruments, Inc., Palo Alto,
California 94304) at 40,000 rpm and at a temperature of 20 C.
Changes in solute concentration were detected by Rayleigh inter-
ference and 275 nm absorbance scans. 153 scans were recorded
during 3 h 40 min.
5.5. Mass spectrometry
0.3 ml of APP-1 at 1.3 mg/ml was dialyzed against Millipore
water in a 3 kDa MWCO dialysis tubing (Spectropore). The dialyzed
protein sample was subjected to electrospray mass spectrometry
under acidic and neutral conditions at the Astbury Centre,
University of Leeds.
5.6. Inductively coupled plasma mass spectrometry (ICP-MS)
APP-1 (4 ml of 1.43 mg/ml) was dialyzed against chelex treated
Millipore water in dialysis tubing that had been EDTA treated to
remove contaminating metal ions. The protein and a control
S. Iyer et al. / FEBS Open Bio 5 (2015) 292–302 301sample of the dialysis buffer were submitted for metal ion analysis
by ICP-MS using Agilent Technologies 4500 (School of Analytical
Sciences, University of Shefﬁeld). Instrumental calibration was
achieved through the use of a single multi-element standard solu-
tion (10 lg/ml).
5.7. APP activity assay
Enzyme activity was assayed by HPLC using bradykinin (40 lM;
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) as the substrate and UV
absorbance (214 nm) to quantify the reaction product, des-Arg-
bradykinin [18]. Reactions were carried out in 50 ll of 0.1 M Tris/
HCl, pH 8.0 at 25 C with 6 ng of recombinant protein and were ter-
minated by the addition of 10 ll of 8% triﬂuoroacetic acid. RP-HPLC
was performed using a 25-cm  0.45 mm C18, 5 lm column
(Phenomenex, Macclesﬁeld, Cheshire, England) and a solvent gra-
dient ranging from 18% to 70% (v/v) acetonitrile in 0.1% triﬂuo-
roacetic acid over 20 min and ﬂow rate of 1 ml min1. Inhibition
of APP-1 activity by 10 lM apstatin was performed by pre-incubat-
ing inhibitor with enzyme for 10 min prior to starting the reaction
by the addition of substrate.
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